The STEP study confirmed that weekly 2.
4 mg of the GLP-1 receptor agonist semaglutide was effective in reducing body weight in obese people, regardless of whether they had diabetes
.
Semaglutide is the second GLP-1 receptor agonist approved for weight management, the first being liraglutide
.
We investigated the difference in efficacy and adverse events of semaglutide 2.
4 mg subcutaneously once weekly or liraglutide 3.
0 mg subcutaneously once daily in overweight or obese people
.
4 mg semaglutide or 3.
0 mg daily subcutaneous liraglutide in overweight or obese people
.
We investigated the difference in efficacy and adverse events of semaglutide 2.
4 mg subcutaneously once weekly or liraglutide 3.
0 mg subcutaneously once daily in overweight or obese people
.
This study was conducted in 19 clinical centers in the United States and was followed up until May 2021.
It is a randomized, open, 68-week phase 3b trial with a BMI of 30 or more or 27 and 1 or more weight-related Patients with comorbidities but no diabetes participated in the study.
On the basis of diet and exercise, patients were randomized to receive 2.
4 mg of semaglutide once a week (n=126) and 3.
0 mg of liraglutide once a day ( n=127) or placebo (n=85)
.
The primary endpoint of the study was weight change at 68 weeks
.
The mean patient age was 49 years, 265 women, mean weight 104.
5 kg, mean body mass index 37.
5, 319 (94.
4%) completed the trial and 271 (80.
2%) completed the treatment
.
The mean weight change from baseline was -15.
8% in the semaglutide group, -6.
4% in the liraglutide group, and -1.
9% in the placebo group
.
Compared with liraglutide, participants in the semaglutide group had an advantage in weight loss of 10% or more, 15% or more, and 20% or more, respectively, 70.
9% vs 25.
6% (OR=6.
3) , 55.
6% vs 12.
0% (OR=7.
9), 38.
5% vs 6.
0% (OR=8.
2)
.
The discontinuation rate for any reason was 13.
5% in the semaglutide group and 27.
6% in the liraglutide group
.
The reported rate of gastrointestinal adverse events was 84.
1% in the semaglutide group and 82.
7% in the liraglutide group
.
The mean weight change from baseline was -15.
8% in the semaglutide group, -6.
4% in the liraglutide group, and -1.
9% in the placebo group
.
The mean weight change from baseline was -15.
8% in the semaglutide group, -6.
4% in the liraglutide group, and -1.
9% in the placebo group
.
Weight control effect of semaglutide vs liraglutide
Weight Control Effects of Semaglutide vs Liraglutide Weight Control Effects of Semaglutide vs LiraglutideThe study concluded that in obese or overweight non-diabetic patients, once-weekly semaglutide was more effective than once-daily liraglutide for weight loss
.
Original Source:
Domenica M.
Rubino et al.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial.
JAMA , January 11, 2022
.
.
In obese or overweight non-diabetic patients, once-weekly semaglutide was superior to once-daily liraglutide for weight loss
.
Original Source:
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial.
JAMA LEAVES
THIS
